Sabby Management’s CASI Pharmaceuticals CASI Stock Holding History

Sabby Management’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-20,254	Closed	-$217K	–	330
2015 Q3	$217K	Sell	20,254 -4,066	-17%	-$58.5K	0.01%	343
2015 Q2	$0	Buy	+24,320	New	+$364K	﹤0.01%	331
2015 Q1	–	Sell	-83,609	Closed	-$1.11M	–	301
2014 Q4	$1.11M	Buy	83,609 +4,760	+6%	+$74.7K	0.04%	153
2014 Q3	$1.41M	Buy	+78,849	New	+$1.4M	0.05%	138
2014 Q2	–	Sell	-106,522	Closed	-$1.95M	–	263
2014 Q1	$1.95M	Sell	106,522 -22,471	-17%	-$425K	0.11%	109
2013 Q4	$2.21M	Buy	128,993 +11,097	+9%	+$188K	0.14%	79
2013 Q3	$2.06M	Buy	117,896 +637	+0.5%	+$12.1K	0.13%	82
2013 Q2	$2.37M	Buy	+117,259	New	+$2.27M	0.16%	89

Other funds holding CASI

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Moors & Cabot Boston, Massachusetts $2.57B AUM 37.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Sabby Management's CASI Position: Q4 2015 in Review

Sabby Management sold out of CASI Pharmaceuticals (CASI) in Q4 2015, closing a stake of 20,254 shares — an estimated $217K sold.

Sabby Management first reported a position in CASI in Q2 2013 and held it in 8 quarters. The position peaked at $2.37M in Q2 2013. 30 funds tracked by Wall St. Rank hold CASI as of Q4 2015.

Sabby Management reported no remaining CASI Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Sabby Management sold 20,254 CASI Pharmaceuticals shares in Q4 2015, an estimated $217K.
Sabby Management first reported a position in CASI Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Sabby Management's CASI Pharmaceuticals position peaked at $2.37M in Q2 2013.
30 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.